The firm Cabinet Carrel (Alexandra Carrel, partner, and Françoise Escoffier, of counsel) and BG2V (Stanislas Richoillez, partner, and Mathilde Périer, associate) assisted Anagenesis Biotechnologies in raising capital for the second time since its creation in 2011.

Boehringer Ingelheim Venture Fund (BIVF) and Cap Innov’Est (CIE), a French inter-regional seed fund, which already holds capital in Anagenesis, invested 3 million euros in the capital.

Anagenesis Biotechnologies (Anagenesis) is a biotech company developing therapies for treating genetic muscle degenerative diseases related to aging.

The capital raised will be invested in the pre-clinical work necessary for developing a medication for fighting against Duchenne muscular dystrophy (DMD).  The capital raised will allow the company to enter a new value-creation phase by identifying the main reasons for the disease.

Anagenesis, which has already received two private investments, from both the AFM (French Muscular Dystrophy Association) to develop applications in the therapeutic skeletal muscle field, and from Cap Innov’Est, aims to become the worldwide leader in the treatment of muscular diseases.

Cabinet Carrel advised Anagenesis on all of the IP and contractual aspects necessary for carrying out the transaction, confirming its expertise in the development of innovative companies.

BG2V assisted Anagenesis with all of the corporate aspects related to the raising the capital, confirming the firm’s expertise in capital development and in assisting biotechnology companies.




Anagenesis’s lawyers:

  • Cabinet Carrel, with Alexandra Carrel, partner, and Françoise Escoffier, of counsel, for the contractual and intellectual property aspects
  • BG2V, with Stanislas Richoillez, partner, and Mathilde Périer, associate, for the corporate aspects


Boehringer Ingelheim Venture Fund’s lawyers:

  • Mc Dermott, with Nicolas Lafont, partner, and Stephan de Groër, associate.


About Cabinet Carrel

Cabinet Carrel is a boutique firm in Paris and Geneva, specialized in the innovation and transfer of technologies.

Cabinet Carrel advises biotechnology, medical equipment, research and digital services companies and academic institutions within the framework of strategic partnerships and joint ventures, research collaboration, cooperation agreements and licensing agreements, and for the development (including clinical) of their products.  The firm also assists its clients in creation, financing, acquisition or corporate restructuring transactions, mainly for the contractual, intellectual property and regulatory aspects

To learn more:

Press contact: Judith Parker – Tel: +33 145630159 – [email protected]


About BG2V:

BG2V is an independent French law firm created in 2010.  With more than 30 lawyers, including 11 partners, BG2V offers full service to its clients in all business law fields.

Recognized for their expertise and personal commitment, our partners, accompanied by their specialized teams, work in the fields of corporate/mergers-acquisitions, private equity, distressed companies, tax and intellectual property/new technologies law, litigation, and commercial, criminal, employment and real estate law.  We provide customized, high-quality services to our clients at a controlled cost.

BG2V’s lawyers work both in French and English and are admitted to practice in France with certain lawyers being admitted to practice in the United States (New York Bar).  For the firm’s cross-border cases (notably in continental Europe, in Anglo-Saxon countries and in the Middle East), the firm has also established preferred relationships with foreign law firms who share the same degree of excellence and legal expertise.

To learn more:

Press contact: Maria Dias, General Secretary – Tel: 01 48 88 60 60 – [email protected]